​

Monte Rosa Therapeutics Ownership | Who Owns Monte Rosa Therapeutics?

OverviewForecastRevenueFinancialsChart

Monte Rosa Therapeutics Ownership Summary

Monte Rosa Therapeutics is owned by 103.92% institutional investors, 0.59% insiders. Nea management company is the largest institutional shareholder, holding 11.74% of GLUE shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.77% of its assets in Monte Rosa Therapeutics shares.

GLUE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMonte Rosa Therapeutics103.92%0.59%-4.51%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company7.69M11.74%$126.54M
Price t rowe associates inc /md/6.72M10.25%$110.55M
Blackrock funding, inc. /de5.64M8.60%$92.74M
Tcg crossover management4.62M7.05%$76.03M
Bvf inc/il4.46M6.81%$73.38M
Baker bros. advisors lp4.35M6.63%$71.49M
Suvretta capital management4.23M6.45%$69.53M
Vestal point capital, lp3.60M5.50%$59.28M
State street3.35M5.12%$55.17M
Braidwell lp3.21M4.89%$52.75M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Versant venture management3.18M37.00%$52.32M
Nea management company7.69M7.19%$126.54M
Aisling capital management lp1.56M5.37%$25.59M
Silverarc capital management2.00M3.36%$32.93M
Bvf inc/il4.46M2.34%$73.38M
Tcg crossover management4.62M2.18%$76.03M
Suvretta capital management4.23M1.78%$69.53M
Braidwell lp3.21M1.76%$52.75M
Vestal point capital, lp3.60M1.66%$59.28M
Exome asset management179.48K1.53%$2.95M

Top Buyers

HolderShares% AssetsChange
Vestal point capital, lp3.60M1.66%2.83M
Braidwell lp3.21M1.76%2.26M
Price t rowe associates inc /md/6.72M0.01%1.60M
American century companies2.81M0.02%1.48M
Blackrock funding, inc. /de5.64M0.00%1.46M

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors---3.73M
Versant venture management3.18M37.00%-1.20M
Readystate asset management lp---287.00K
Fmr1.02M0.00%-275.79K
Invesco102.20K0.00%-260.02K

New Positions

HolderShares% AssetsChangeValue
Bellevue group1.25M0.49%1.25M$20.56M
Frazier life sciences management1.00M0.42%1.00M$16.45M
Janus henderson group685.93K0.01%685.93K$11.29M
Norges bank445.87K0.00%445.87K$3.09M
Vanguard fiduciary trust407.08K0.00%407.08K$6.70M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-6.00
Clearstead advisors-8.00
Turning point benefit group-14.00
Caitong asset management-27.00
Capital performance advisors llp-29.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202618913.86%86,330,08433.91%1031.70%13229.41%415.13%
Dec 31, 202565-51.13%12,491,437-79.19%150.28%46-24.59%9-77.50%
Sep 30, 202547-59.83%19,971,709-67.89%240.42%21-72.37%16-11.11%
Jun 30, 20251167.41%62,164,3354.44%751.44%7570.45%18-60.87%
Mar 31, 20256-94.44%15,774,831-74.13%190.35%3-95.77%1-94.12%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.34M2.77%-
State Street® SPDR® S&P® Biotech ETF2.17M2.57%-21.68K
T. Rowe Price Health Sciences2.00M2.50%8.96K
US Small-Cap Growth II Equity Comp1.99M2.48%280.13K
T. Rowe Price New Horizons1.99M2.48%-17.20K
Avantis US Small Cap Value ETF2.05M2.43%-
HBM Healthcare Investments AG Ord1.82M2.16%416.67K
iShares Russell 2000 ETF1.43M1.69%12.03K
Fidelity Growth Compy Commingled Pl O970.82K1.58%-
T. Rowe Price New Horizons Tr-Z887.19K1.44%1.28K

Recent Insider Transactions

DateNameRoleActivityValue
Jun 01, 2026Warmuth Markus President & CEOSell$9.23K
Jun 01, 2026Warmuth Markus President & CEOSell$97.02K
May 29, 2026Townson Sharon Chief Scientific OfficerSell$119.22K
May 27, 2026Champoux Jennifer Chief Operating OfficerSell$43.50K
May 22, 2026Champoux Jennifer Chief Operating OfficerSell$41.34K

Insider Transactions Trends

DateBuySell
2026 Q2-9
2026 Q1-14
2025 Q2-1
2025 Q11-
2024 Q4-3

GLUE Ownership FAQ

Who Owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics shareholders are primarily institutional investors at 103.92%, followed by 0.59% insiders and -4.51% retail investors. The average institutional ownership in Monte Rosa Therapeutics's industry, Biotech Stocks , is 35.75%, which Monte Rosa Therapeutics exceeds.

Who owns the most shares of Monte Rosa Therapeutics?

Monte Rosa Therapeutics’s largest shareholders are Nea management company (7.69M shares, 11.74%), Price t rowe associates inc /md/ (6.72M shares, 10.25%), and Blackrock funding, inc. /de (5.64M shares, 8.60%). Together, they hold 30.59% of Monte Rosa Therapeutics’s total shares outstanding.

Does Blackrock own Monte Rosa Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Monte Rosa Therapeutics.

Who is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested, with 37.00% of its assets in 3.18M Monte Rosa Therapeutics shares, valued at 52.32M$.

Who is the top mutual fund holder of Monte Rosa Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Monte Rosa Therapeutics shares, with 2.77% of its total shares outstanding invested in 2.34M Monte Rosa Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools